COVID-19 vaccination outcomes in patients with a solid malignancy: Insights from extensive real-world data and propensity score matched analyses - 09/05/24
Résumé |
Objectives |
This nationwide, multicentric, retrospective analysis of 1,126,946 COVID-19 cases (March 2020-June 2022) aims to elucidate the impact of COVID-19 vaccination on mortality in patients with a sole solid malignancy.
Methods |
Using data from the national digital medical record repository, outcomes were compared among fully vaccinated and nonvaccinated cohorts, factoring in gender, virus type, age, vaccination status, vaccine type, and cancer type. Logistic regression calculated odds ratios (OR) and their significance.
Results |
Among 6,050 patients with both cancer and comorbidities, 1,797 had only solid malignancy. Vaccinated individuals in this group had reduced mortality rates, especially those >63 years (OR 0.169 [95% confidence interval [CI] 0.090-0.317]; P < .001). Lower deaths were observed in non-ICU (OR 0.193 [95% CI 0.097-0.382]; P < .001) and ICU cases (OR 0.224 [95% CI 0.077-0.646]; P = .003), with both vaccine types. No statistically significant benefits were observed against delta and omicron variants. Intrathoracic malignancies (OR 0.376 [95% CI 0.146-0.971]; P = .043) and palliative treatment (OR 0.384 [95% CI 0.192-0.766]; P = .006) showed vaccination benefits. Logistic regression revealed a higher fatal risk in nonvaccinated males >63. Propensity score matching supported these outcomes.
Conclusions |
Patients with sole solid malignancies face elevated COVID-19 mortality risk, particularly without active cytostatic therapy, with advanced disease on palliative treatment, or intrathoracic malignancies.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Vaccinated solid cancer patients >63 show reduced mortality. |
• | Vaccination reduces mortality in non-ICU and ICU, irrespective of type. |
• | No significant vaccination benefits seen with variants. |
• | Intrathoracic malignancies and palliative care show vaccination benefits. |
• | Propensity score matching supported findings. |
Key Words : Cancer, Chemotherapy, Mortality
Plan
Conflicts of interest: None to report. |
Vol 52 - N° 6
P. 678-682 - juin 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.